As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
© Jira Pliankharom / Getty Images / iStock
Featured Research: Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest
SARS-CoV-2 and its associated disease, COVID-19, has infected over seven million people world-wide, including two million people in the United States. Passive immunotherapy by the transfusion of convalescent plasma donated by COVID-19 recovered patients might be an effective option to combat the virus, especially if used early in the course of disease.
In this study, Hartman and colleagues describe treating a series of COVID-19 patients with severe or life-threatening disease with convalescent plasma who demonstrated favorable clinical outcomes when compared to those reported in the literature to date.
Articles
-
-
The role of serotonin and diet in the prevalence of irritable bowel syndrome: a systematic review
-
Lung mechanics in type L CoVID-19 pneumonia: a pseudo-normal ARDS
-
Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy
-
Developing a diagnostic method for latent tuberculosis infection using circulating miRNA
-
Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles
-
Total lymphocyte count in cancer patients with lymphopenia treated with intravenous vitamin C: Results of an observational study
-
C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis
-
Glyceraldehyde-3-phosphate dehydrogenase is overexpressed in colorectal cancer onset
-
Comparative in vitro cytotoxic, anti-inflammatory and anti-microbiological activities of two indigenous Venda medicinal plants
© enotmaks / Fotolia
Why publish with us
- Home for all valid research within pre-clinical and translational medicine
- Gold open access and compatible with growing funder mandates
- Specialised sections with expert Section Editors and Editorial Board
- Free access to all content, ensuring a wide dissemination of articles
- High website accesses with more than 18,900 page visits in the last 12 months
- Companion journal to Journal of Translational Medicine
Aims and scope
Translational Medicine Communications is an interdisciplinary forum for all scientifically valid research from across translational medicine. We publish research that focuses on the biology of disease, as well as preclinical and basic research that is closely associated with medicine. Translational Medicine Communications will also consider reviews, methodology articles, protocols and commentaries.
Our aim is to improve transparency and reproducibility within translational medicine, which is why we consider research papers regardless of outcome or significance of findings, as well as protocols for future research. We aim to serve the translational science community by publishing all scientifically valid and technically sound articles and we are dedicated to facilitating the communication between basic and clinical science.
Translational Medicine Communications is the companion journal to Journal of Translational Medicine.
Journal of Translational Medicine considers articles focusing on information derived from human experimentation to optimise the communication between basic and clinical science.
Editor-in-Chief
Francesco Marincola, Refuge Biotechnologies, USA
Annual Journal Metrics
-
Speed
54 days to first decision for reviewed manuscripts only
52 days to first decision for all manuscripts
89 days from submission to acceptance
20 days from acceptance to publication
Usage
27,765 Downloads
8 mentions
